# Monoclonal Antibody Technology Core

> **NIH NIH P01** · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2022 · $405,000

## Abstract

Summary
Improving the durability and efficacy of the antibody response induced by novel influenza vaccines, and
generating novel anti-influenza therapeutic reagents are central goals of influenza research. A more durable
influenza vaccine and broad-spectrum therapeutics are important for protection against mutant and novel
influenza strains that cause annual infection and pandemics. Monoclonal antibodies (mAbs) have provided
major advances both in our thinking and for design of more broadly-protective vaccines and as potential broad-
spectrum anti-influenza therapeutics. While hemagglutinin (HA) remains a mainstay as a vaccine or
therapeutic target, antibodies to neuraminidase (NA) and other influenza proteins are much less studied but
are also protective and may bind a wider range of influenza strains. In the various projects of this program
mAbs against influenza HA, NA, matrix protein (M1) and nuclear protein (NP) will be used to identify epitopes,
to evaluate known and novel epitopes for breadth and potency of protection, to learn new mechanisms of
protection, and to evaluate trial vaccine efficacy. Thus the four projects in this program will use the mAb core
as a central resource in order to inform on antigen and vaccine design. Further, the studies proposed will
generate large panels of mAbs that may themselves be valuable as therapeutic reagents to treat influenza
infections. For this we will produce antibodies from novel cohorts that we have identified that preferentially
target conserved epitopes on HA, and at substantially greater frequencies to conserved epitopes on other
influenza proteins including NA, NP and M1. The core will also help the projects evaluate trial vaccine efficacy
and specificity at the monoclonal antibody level.

## Key facts

- **NIH application ID:** 10468074
- **Project number:** 5P01AI097092-10
- **Recipient organization:** ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
- **Principal Investigator:** Patrick Christopher Wilson
- **Activity code:** P01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $405,000
- **Award type:** 5
- **Project period:** 2012-08-01 → 2024-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10468074

## Citation

> US National Institutes of Health, RePORTER application 10468074, Monoclonal Antibody Technology Core (5P01AI097092-10). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10468074. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*